N
PSTX

Nuveen’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Nuveen’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-299,297
Closed -$2.87M – 3345
2024
Q4 		$2.87M Sell
299,297
-5,314
-2% -$27.7K ﹤0.01% 2232
2024
Q3 		$871K Sell
304,611
-98,270
-24% -$304K ﹤0.01% 2819
2024
Q2 		$1.18M Buy
402,881
+130,694
+48% +$357K ﹤0.01% 2652
2024
Q1 		$868K Sell
272,187
-10,444
-4% -$34.8K ﹤0.01% 2755
2023
Q4 		$950K Sell
282,631
-82,560
-23% -$213K ﹤0.01% 2754
2023
Q3 		$869K Hold
365,191
– – ﹤0.01% 2630
2023
Q2 		$643K Buy
+365,191
New +$933K ﹤0.01% 2849
2022
Q2 		– Sell
-98,962
Closed -$463K – 3529
2022
Q1 		$463K Buy
98,962
+1,368
+1% +$6.17K ﹤0.01% 3040
2021
Q4 		$643K Sell
97,594
-10,090
-9% -$68.7K ﹤0.01% 3002
2021
Q3 		$862K Buy
107,684
+8,288
+8% +$71.1K ﹤0.01% 3043
2021
Q2 		$996K Buy
99,396
+491
+0.5% +$4.4K ﹤0.01% 3007
2021
Q1 		$945K Buy
98,905
+65,203
+193% +$640K ﹤0.01% 2902
2020
Q4 		$370K Buy
33,702
+11,274
+50% +$119K ﹤0.01% 3103
2020
Q3 		$199K Buy
+22,428
New +$255K ﹤0.01% 3161

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Nuveen's PSTX Position: Q1 2025 in Review

Nuveen sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 299,297 shares — an estimated $2.87M sold.

Nuveen first reported a position in PSTX in Q3 2020 and held it in 14 quarters. The position peaked at $2.87M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • Nuveen reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Nuveen sold 299,297 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $2.87M.
  • Nuveen first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 14 quarters.
  • Nuveen's Poseida Therapeutics, Inc. Common Stock position peaked at $2.87M in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Nuveen's 13F filing for Q1 2025, filed 12 May 2025.